Agenda
Specific meetings can focus on any of the following aspects of the management of ART:
- First-line and Switch Strategies Using Current ART Regimens
- Emerging Approaches to Optimize ART
- ART Strategies for Complex HIV Cases
- Integrating New Data From CROI 2020
- Integrating New Data From IAC 2020
The timing and agenda for each individual meeting is as follows:
- Welcome, CME information, and baseline outcomes questions (10 mins)
- Case 1 discussion followed by didactic slides (10-15 mins)
- Case 2 discussion followed by didactic slides (10-15 mins)
- Case 3 discussion followed by didactic slides (10-15 mins)
- Question and answer session, concluding outcomes questions (15-20 mins)
Events
Date / Time
Event Details
Faculty
Program Director
Joseph J. Eron, MD
Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina
Program Director
Princy N. Kumar, MD
Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina
Faculty
Roger Bedimo, MD
Professor of Medicine
Division of Infectious Diseases
University of Texas Southwestern Medical Center
Section Chief
Division of Infectious Diseases
Department of Internal Medicine
VA North Texas Health Care System
Dallas, Texas
Faculty
Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Faculty
Lisa Hightow-Weidman, MD, MPH
Professor of Medicine and Health Behavior
University of North Carolina School of Medicine
Director, Behavior and Technology Lab (BATLab) and UNC
University of North Carolina
Chapel Hill, North Carolina
Faculty
Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Faculty
Mary W. Montgomery, MD
Instructor of Medicine
Harvard Medical School
Associate Professor
Division of Infectious Disease
Department of Medicine
Brigham and Women's Hospital
Boston, Massachusetts
Faculty
Daniel A. Solomon, MD
Instructor of Medicine
Division of Infectious Diseases
Harvard Medical School
Associate Physician
Division of Infectious Diseases
Brigham and Women's Hospital
Boston, Massachusetts
Faculty
Heidi Swygard, MD
Clinical Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Faculty
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Faculty
Marc A. Tribble, MD
Clinical Assistant Professor
Division of Infectious Diseases
Baylor University Medical Center at Dallas
Dallas, Texas
Faculty
Timothy J. Wilkin, MD, MPH
Associate Professor of Medicine
Co-Director, Cornell Clinical Trials Unit
Weill Cornell Medical College
New York, New York
Faculty
David A. Wohl, MD
Professor of Medicine
School of Medicine
Site Leader, AIDS Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Director, North Carolina AIDS Training and Education Center
Chapel Hill, North Carolina
Co-Director, HIV Services
North Carolina Department of Correction
Raleigh, North Carolina
Goal Statement
The goal of this activity is to improve learners’ competence in providing optimal care for HIV-infected patients through the appropriate use of contemporary ARV regimens.
Target Audience
This program is intended for physicians, registered nurses, physician assistants, pharmacists, and other healthcare professionals who provide care for patients with HIV infection.
Learning Objectives
- Integrate best practices in the management of first-line ART and regimen modifications in virologically suppressed patients
- Apply optimized management strategies for patients with HIV who present with complex medical challenges, including virologic failure in the setting of an extensive treatment history and multiclass drug resistance and/or multiple comorbidities and comedications
- Incorporate the latest data and expert insights on emerging innovative ARV treatment paradigms into the individualized care of persons with HIV infection, as appropriate
- Appropriately counsel patients regarding the anticipated clinical role of new and investigational ART regimens
Accreditation
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Credit Designation
CCO designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.5 contact hours.
Continuing Pharmacy Education
CCO designates this continuing education activity for 2.5 contact hours (0.25 CEUs) of the Accreditation Council for Pharmacy Education. Individual topic ACPE UANs available within the Event Date tab.
Type of Activity: Application
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.